CADL — Candel Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $260.14m
- $169.99m
- 40
- 18
- 23
- 16
Annual cashflow statement for Candel Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.7 | -36.1 | -18.8 | -37.9 | -55.2 |
| Depreciation | |||||
| Non-Cash Items | 6.74 | 14.6 | -13.5 | 3.26 | 26.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.77 | -0.876 | 0.071 | -0.525 | 0.346 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -9.07 | -22.2 | -31.4 | -34.2 | -27 |
| Capital Expenditures | -1.48 | -1.83 | -1.3 | -0.457 | -0.016 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 39.9 | 0 | — | 0.177 | 0 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 38.5 | -1.83 | -1.3 | -0.28 | -0.016 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.49 | 71.8 | 20 | -0.121 | 94.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 29.9 | 47.7 | -12.7 | -34.6 | 67.2 |